School of Medicine
Showing 141-160 of 342 Results
-
Michele Berk
Assistant Professor of Psychiatry and Behavior Sciences (Child and Adolescent Psychiatry and Child Development)
Current Research and Scholarly InterestsThe focus of my research is on adolescent suicidal and self-harm behavior. I am currently one of four Principal Investigators of a multisite NIMH-sponsored RCT of DBT for adolescents at high risk for suicide (NCT01528020: Collaborative Adolescent Research on Emotions and Suicide [CARES], PI: Linehan, McCauley, Berk, & Asarnow) aimed at evaluating the efficacy of DBT with adolescents compared to a combined individual and group supportive therapy control condition (IGST).
-
Rebecca A. Bernert, PhD, ABPP, FT
Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
BioI am an Assistant Professor of Psychiatry and Behavioral Sciences and a licensed clinical psychologist in the Stanford University School of Medicine. I am a suicidologist, with subspecialty expertise in clinical trials, epidemiology, and suicide prevention best practices. I have joint specialty in behavioral sleep medicine, treatment development, and thanatology. I am Founding Director of The Stanford Suicide Prevention Research Laboratory, and Co-Chair a number of initiatives to support multidisciplinary efforts in suicide prevention. Our program utilizes cognitive, biological (e.g., fMRI), and behavioral testing paradigms, with an emphasis on translational therapeutics across the lifespan. Our mission is to identify novel therapeutics, including seminal work to establish the subfield of sleep and suicide prevention. A special focus is the development of rapid-action, low-risk interventions for the prevention of suicide. Our mission is to evaluate transdiagnostic risk factors and biomarkers underlying treatment response that may inform etiology, reduce stigma, and advance innovation. Advocating for its utility as a visible, yet non-stigmatizing warning sign of suicide—our earliest work delineated sleep as a risk factor for suicidal behaviors. Funded by NIH and DOD, we subsequently conducted the first suicide prevention clinical trials, testing efficacy of a rapid-action (6 h) insomnia treatment for suicidal behaviors. These use a mechanisms focus to identify central disease processes (eg, underlying neural circuitry, behavioral factors) for anti-suicidal response. An overarching aim is to harness new technologies to aid risk prediction, precision medicine, and intervention opportunity. We are committed to improving national training practices (e.g., national needs-assessment of medical training parameters; AI for suicide prevention), and lead hospital best practices for safety in screening, triage, and postvention.
Regarding translation to policy, I have served as a content expert for nationally-directed health initiatives with NIH, VA, DOD, DARPA, SAMHSA, CDC, and The White House. I recently led development of the CA 2020-25 Statewide Strategy for Suicide Prevention, following invited testimony (CA State Assembly) and a commissioned Policy Brief on suicide prevention best practices. Advisory and advocacy work centers on how research guides public health policy and implementation. I am especially committed to initiatives promising impact to suicide prevention on a broad scale, including universal strategies for lethal means restriction and real-time surveillance of suicidal behaviors. To this end, I have been honored to serve as a content expert to The White House Office of Science and Technology for initiatives focused on technology innovation and led advisory work promoting suicide deterrent systems for private organizations and public sites, such as the Golden Gate Bridge. I have consulted for technology companies, as well as private industry and healthcare partners.
Inspired by maternity leaves coinciding with the above work, I have a separate research line examining organizational development, inclusive practices, sleep and employee wellness. This addresses disparate impact of institutional and federal medical leave practices on recruitment and retention of women. Our program focuses on cost-effective policy for diversity training and reduced attrition of women in medicine, law, STEM and technology fields. As such, I am dedicated to spearheading development of a Stanford Center for Policy, Inclusive Practices, and Equity Education.
To donate or partner with us, please contact Deborah Stinchfield (Stanford Medical Center Development) medicalgiving@stanford.edu or please contact us directly. -
Daniel Bernstein
Alfred Woodley Salter and Mabel G. Salter Endowed Professor of Pediatrics
Current Research and Scholarly Interests1. Using iPSC-derived cardiomyocytes to understand hypertrophic cardiomyopathy and heart failure associated with congenital heart disease.
2. Role of alterations in mitochondrial dycamics and function in normal physiology and disease.
3. Differences between R and L ventricular responses to stress,
4. Immune biomarkers of risk after pediatric VAD implantation.
5. Biomarkers for post-transplant lymphoproliferative disorder. -
Jon Bernstein
Professor of Pediatrics (Genetics) and, by courtesy, of Genetics
Current Research and Scholarly InterestsMy research is focused on the diagnosis, discovery and delineation of rare genetic conditions with a focus of neurodevelopmental disorders. This work includes the application of novel computational methods and multi-omics profiling (whole genome sequencing, RNA sequencing, metabolomics). I additionally participate in an interdisciplinary project to develop induced pluripotent stem cell (iPSC) models of genetic neurodevelopmental disorders..
-
Wendy J. Bernstein
Adjunct Clinical Instructor, Psychiatry and Behavioral Sciences
BioSenior Community Psychiatrist, Wellness Equity Alliance, Medical Director, Project ECHO and Telemedicine for Severe Mental Illness Track to support the Mental Health of SGBV survivors in Democratic Republic of Congo project. Past Associate Medical Director at Casa del Sol, specialty mental health clinic of La Clinica de la Raza in Oakland California from 2013 to July 2021. Previously at Kaiser Permanente, Northern California, from 2000 to 2013, and Contra Costa County Older Adults Clinics from 1995-2000. Graduate of McGill University Faculty of Medicine, Montreal, Canada, and Boston University Psychiatry Residency. Interests include global health, community mental health, Latinx and underserved populations, women's health, and elder care.
-
William Berquist
Professor of Pediatrics (Gastroenterology), Emeritus
Current Research and Scholarly InterestsGastroenterology, gastointestinal motility, clinical management of pediatric liver transplant recipients.
-
Gerald Berry
Richard Kempson, M.D., Professor of Surgical Pathology
Current Research and Scholarly InterestsCardiopulmonary and pulmonary transplant medicine; diagnostic surgical pathology
-
Mark Francis Berry, MD
Mylavarapu Rogers Professor of Cardiothoracic Surgery
BioDr. Berry joined the Division of Thoracic Surgery at Stanford in August 2014. He came to Stanford from Duke University, where he had most recently served as Associate Professor. He received his medical degree at the University of Pennsylvania School of Medicine after receiving bachelors and masters degrees in Electrical Engineering at the University of Pennsylvania. He completed his residency in Cardiothoracic Surgery at Duke University Medical Center after performing a residency in General Surgery at the Hospital of the University of Pennsylvania. His Cardiothoracic Surgical training included a year dedicated to Minimally Invasive General Thoracic Surgery, a period that also included an American Association for Thoracic Surgery sponsored Traveling Fellowship at the University of Pittsburgh.
Dr. Berry practices all aspects of thoracic surgery, including procedures for benign and malignant conditions of the lung, esophagus, and mediastinum. He has a particular interest in minimally invasive techniques, and has extensive experience in treating thoracic surgical conditions using video-assisted thoracoscopic surgical (VATS), laparoscopic, robotic, endoscopic, and bronchoscopic approaches. He serves as the co-Director of the Stanford Minimally Invasive Thoracic Surgery Center (SMITS), and has both directed and taught in several minimally invasive thoracic surgery courses.
Dr. Berry also has a Masters of Health Sciences in Clinical Research from Duke University. His clinical research activities mirror his clinical interests and activities in optimizing short-term and long-term outcomes of patients with thoracic surgical conditions. He has more than 150 peer-reviewed publications, most of which are related to both the use of minimally invasive thoracic surgical techniques as well as evaluating outcomes after treatment of thoracic malignancies. His clinical practice and his research both focus on choosing the most appropriate treatment and approach for patients based on the individual characteristics of the patient and their disease process. -
Edward Bertaccini
Professor of Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly Interestsmolecular modeling of anesthetic-protein interactions, molecular modeling of the ligand-gated ion channels
-
Alice Bertaina MD, PhD
Lorry I. Lokey Professor
On Leave from 03/01/2024 To 04/30/2024Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.
-
Carolyn Bertozzi
Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology
BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.
Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.
The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.
Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.
